In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent
Autoři
BACCARANI, M. (garant), I. IACOBUCCI, S. CHIARETTI, R. FOA, P. BALASUBRAMANIAN, E. PAIETTA, L. FORONI, S. JEROMIN, B. IZZO, O. SPINELLI, N. VARMA, S. MENIF, C. TERRAGNA, T. SETH, A. BIDET, D. CORIU, F. LUNGHI, Jiří MAYER (203 Česká republika, domácí), B. SCAPPINI, S. LANGABEER, J. MAIER, E. BURT, A. CANDONI, F. ALBANO, M. LUPPI, I. ZUPAN, T. LION, R. ZADRO, F. DI RAIMONDO, B. POOPAK, G. REGE-CAMBRIN, M. ANNUNZIATA, A. AYALA, V. SALINAS-VIEDMA, A. INES PADO, B. MILNER, S. GALIMBERTI, J. JANSSEN, V. POLLI, L. COMBA, B. BORSELLINO, O. ANNIBALI, M. CRUGNOLA a F. PASSAMONTI
Philadelphia-chromosome positive (Ph+), BCR-ABL1+ acute lymphoblastic leukemia (ALL) is a distinct entity that is characterized by specific genomic alterations, low sensitivity to chemotherapy, unstable responsiveness to tyrosine kinase inhibitors (TKIs), and a poor prognosis.
BACCARANI, M., I. IACOBUCCI, S. CHIARETTI, R. FOA, P. BALASUBRAMANIAN, E. PAIETTA, L. FORONI, S. JEROMIN, B. IZZO, O. SPINELLI, N. VARMA, S. MENIF, C. TERRAGNA, T. SETH, A. BIDET, D. CORIU, F. LUNGHI, Jiří MAYER, B. SCAPPINI, S. LANGABEER, J. MAIER, E. BURT, A. CANDONI, F. ALBANO, M. LUPPI, I. ZUPAN, T. LION, R. ZADRO, F. DI RAIMONDO, B. POOPAK, G. REGE-CAMBRIN, M. ANNUNZIATA, A. AYALA, V. SALINAS-VIEDMA, A. INES PADO, B. MILNER, S. GALIMBERTI, J. JANSSEN, V. POLLI, L. COMBA, B. BORSELLINO, O. ANNIBALI, M. CRUGNOLA a F. PASSAMONTI. In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. Leukemia. London: Nature Publishing Group, 2020, roč. 34, č. 3, s. 929-931. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-019-0591-9.
@article{1740658, author = {Baccarani, M. and Iacobucci, I. and Chiaretti, S. and Foa, R. and Balasubramanian, P. and Paietta, E. and Foroni, L. and Jeromin, S. and Izzo, B. and Spinelli, O. and Varma, N. and Menif, S. and Terragna, C. and Seth, T. and Bidet, A. and Coriu, D. and Lunghi, F. and Mayer, Jiří and Scappini, B. and Langabeer, S. and Maier, J. and Burt, E. and Candoni, A. and Albano, F. and Luppi, M. and Zupan, I. and Lion, T. and Zadro, R. and di Raimondo, F. and Poopak, B. and RegeandCambrin, G. and Annunziata, M. and Ayala, A. and SalinasandViedma, V. and Ines Pado, A. and Milner, B. and Galimberti, S. and Janssen, J. and Polli, V. and Comba, L. and Borsellino, B. and Annibali, O. and Crugnola, M. and Passamonti, F.}, article_location = {London}, article_number = {3}, doi = {http://dx.doi.org/10.1038/s41375-019-0591-9}, keywords = {acute lymphoblastic leukemia}, language = {eng}, issn = {0887-6924}, journal = {Leukemia}, title = {In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent}, url = {https://www.nature.com/articles/s41375-019-0591-9}, volume = {34}, year = {2020} }
TY - JOUR ID - 1740658 AU - Baccarani, M. - Iacobucci, I. - Chiaretti, S. - Foa, R. - Balasubramanian, P. - Paietta, E. - Foroni, L. - Jeromin, S. - Izzo, B. - Spinelli, O. - Varma, N. - Menif, S. - Terragna, C. - Seth, T. - Bidet, A. - Coriu, D. - Lunghi, F. - Mayer, Jiří - Scappini, B. - Langabeer, S. - Maier, J. - Burt, E. - Candoni, A. - Albano, F. - Luppi, M. - Zupan, I. - Lion, T. - Zadro, R. - di Raimondo, F. - Poopak, B. - Rege-Cambrin, G. - Annunziata, M. - Ayala, A. - Salinas-Viedma, V. - Ines Pado, A. - Milner, B. - Galimberti, S. - Janssen, J. - Polli, V. - Comba, L. - Borsellino, B. - Annibali, O. - Crugnola, M. - Passamonti, F. PY - 2020 TI - In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent JF - Leukemia VL - 34 IS - 3 SP - 929-931 EP - 929-931 PB - Nature Publishing Group SN - 08876924 KW - acute lymphoblastic leukemia UR - https://www.nature.com/articles/s41375-019-0591-9 L2 - https://www.nature.com/articles/s41375-019-0591-9 N2 - Philadelphia-chromosome positive (Ph+), BCR-ABL1+ acute lymphoblastic leukemia (ALL) is a distinct entity that is characterized by specific genomic alterations, low sensitivity to chemotherapy, unstable responsiveness to tyrosine kinase inhibitors (TKIs), and a poor prognosis. ER -
BACCARANI, M., I. IACOBUCCI, S. CHIARETTI, R. FOA, P. BALASUBRAMANIAN, E. PAIETTA, L. FORONI, S. JEROMIN, B. IZZO, O. SPINELLI, N. VARMA, S. MENIF, C. TERRAGNA, T. SETH, A. BIDET, D. CORIU, F. LUNGHI, Jiří MAYER, B. SCAPPINI, S. LANGABEER, J. MAIER, E. BURT, A. CANDONI, F. ALBANO, M. LUPPI, I. ZUPAN, T. LION, R. ZADRO, F. DI RAIMONDO, B. POOPAK, G. REGE-CAMBRIN, M. ANNUNZIATA, A. AYALA, V. SALINAS-VIEDMA, A. INES PADO, B. MILNER, S. GALIMBERTI, J. JANSSEN, V. POLLI, L. COMBA, B. BORSELLINO, O. ANNIBALI, M. CRUGNOLA a F. PASSAMONTI. In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. \textit{Leukemia}. London: Nature Publishing Group, 2020, roč.~34, č.~3, s.~929-931. ISSN~0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-019-0591-9.